Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients

Radiotherapy and Oncology

Volumn 70, Issue 3, 2004, Pages 261-264

  Rades, Dirk ^a   Fehlauer, Fabian ^a   Bajrovic, Amira ^a   Mahlmann, Birgit ^b   Richter, Eckart ^b   Alberti, Winfried ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Acute toxicity; Amifostine; Head and neck cancer; Radiotherapy

Indexed keywords

AMIFOSTINE; CISPLATIN; FLUOROURACIL;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; UTILIZATION REVIEW;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG HYPERSENSITIVITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; MOUTH MUCOSA; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; STOMATITIS; VOMITING; XEROSTOMIA;

EID: 1942535173     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2003.10.005     Document Type: Article

References (19)

1. Andreassen C.N., Grau C., Lindegaard J.C. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol. 13:2003;62-72.
2. Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 29:(19):2002;80-83.
3. Antonadou D., Pepelassi M., Synodinou M., Puglisi M., Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 52:2002;739-747.
4. Atahan I.L., Ozyar E., Sahin S., Yildiz F., Yalcin B., Karaduman A. Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy. Br J Dermatol. 143:2000;1072-1073.
5. Bourhis J., De Crevoisier R., Abdulkarim B., et al. A randomized study of very accelerated radiotherapy with and without amifostine in advanced head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;1105-1108.
6. Bragg C.M., Conway J., Robinson M.H. The role of intensity-modulated radiotherapy in the treatment of parotid tumors. Int J Radiat Oncol Biol Phys. 52:2002;729-738.
7. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 18:2000;3339-3345.
8. Buntzel J., Kuttner K., Frohlich D., Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 9:1998;505-509.
9. Demiral A.N., Yerebakan O., Simsir V., Alpsoy E. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 32:2002;477-479.
10. Eisbruch A., Kim H.M., Terrell J.E., Marsh L.H., Dawson L.A., Ship J.A. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 50:2001;695-704.
11. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 18:2000;2226-2233.
12. Lindegaard J.C., Crau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol. 57:2000;113-118.
13. McDonald S., Meyerowitz C., Smudzin T., Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys. 29:1994;747-754.
14. Stephens L.C., Ang K.K., Schultheiss T.E., King G.K., Brock W.A., Peters L.J. Target cell and mode of radiation injury in rhesus salivary glands. Radiother Oncol. 7:1986;165-174.
15. Stephens L.C., Schultheiss T.E., Price R.E., Ang K.K., Peters L.J. Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer. 67:1991;1539-1543.
16. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:2000;13-47.
17. Van Asselen B., Dehnad H., Raaijmakers C.P., Roesink J.M., Lagendijk J.J., Terhaard C.H. The dose to the parotid glands with IMRT for oropharyngeal tumors: the effect of reduction of positioning margins. Radiother Oncol. 64:2002;197-204.
18. Vardy J., Wong E., Izard M., Clifford A., Clarke S.J. Life-threatening anaphylactoid reaction of amifostine used in concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs. 13:2002;327-330.
19. Yuhas J.M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2(3-aminopropylamino)- ethylphosphorothioic acid. Cancer Res. 40:1980;1519-1524.